S1PR5 and inflammatory bowel disease: Several other oral small molecule S1P receptor modulators are in clinical development for IBD, including: etrasimod, an agonist of S1P1 receptors and a partial agonist of S1P4 and S1P5 receptors98; mocravimod, an agonist of the S1P1 receptor and a partial agonist of the S1P3 receptor100; and amiselimod, an agonist of S1P1 and S1P5 receptors101.